Edition:
United States

BELLUS Health Inc (BLU.TO)

BLU.TO on Toronto Stock Exchange

0.43CAD
--
Change (% chg)

-- (--)
Prev Close
$0.43
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
151,998
52-wk High
$0.55
52-wk Low
$0.21

Latest Key Developments (Source: Significant Developments)

Bellus Health Q2 ‍revenue $41,000
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Bellus Health Inc :Bellus Health reports financial and operating results for the second quarter ended June 30, 2017.Bellus Health - ‍revenues amounted to $41,000 for three-month period ended June 30, 2017, compared to $585,000 for corresponding period previous year​.Qtrly earnings per share $0.00‍​.  Full Article

Bellus Health reports results for the year ended December 31, 2016
Tuesday, 28 Feb 2017 10:54am EST 

Bellus Health Inc : Bellus Health reports financial and operating results for the year ended December 31, 2016 .Believes its cash position should be sufficient to finance its operations for more than 12 months.  Full Article

Bellus Health and the NEOMED Institute announce agreement for development of treatment for chronic cough
Tuesday, 28 Feb 2017 10:52am EST 

Bellus Health Inc : Bellus Health and the NEOMED Institute announce an exclusive worldwide license agreement for the development of a treatment for chronic cough . Under terms of agreement, Bellus Health will pay neomed an upfront fee of cad $3.2 million . Upfront fee consists of CAD $1.7 million in cash and CAD $1.5 million with 5.8 million bellus health common shares .As per agreement, NEOMED will be entitled to receive a royalty on net sales-based revenues.  Full Article

Bellus Health reports Q2 basic and diluted loss per share $0.01
Tuesday, 9 Aug 2016 07:00am EDT 

Bellus Health Inc : Provides update on project pipeline and reports financial and operating results for the second quarter ended June 30, 2016 .Qtrly basic and diluted loss per share $0.01.  Full Article

Bellus Health says Kiacta did not meet primary efficacy endpoint in phase 3 study
Monday, 20 Jun 2016 08:00am EDT 

Bellus Health Inc : Announces top-line phase 3 results of kiacta for treatment of aa amyloidosis . In study, Kiacta did not meet primary efficacy endpoint in slowing renal function decline . Kiacta was shown to be safe and well tolerated over treatment periods of greater than 4 years .Further analysis of data is ongoing..  Full Article

Bellus Health reports Q1 loss per share C$0.01
Thursday, 12 May 2016 05:00pm EDT 

Bellus Health Inc : Qtrly loss per share C$0.01 .Q1 revenue C$591,000 versus C$786,000.  Full Article